Zobrazeno 81 - 90
of 131
pro vyhledávání: ''
Autor:
Aram F. Hezel, Nabeel Bardeesy, Cyril H. Benes, Jia-Chi Yeo, James T. Webber, Kevan M. Shokat, Travis Sullivan, Benjamin P. Kleinstiver, Roger L. Jenkins, Ultan McDermott, Yusuke Mizukami, Leah J. Damon, Regina K. Egan, Lei Shi, Supriya K. Saha, J. Keith Joung, John D. Gordan, Patricia Greninger, Rebecca S. Levin, Andrew S. Liss, Yasutaka Kato, Andrew X. Zhu, Kimberly M. Rieger-Christ, Mortada S. Najem, Lipika Goyal, Cristina R. Ferrone, Phuong Vu, Mathew J. Garnett
Publikováno v:
Cancer discovery, vol 6, iss 7
Intrahepatic cholangiocarcinoma (ICC) is an aggressive liver bile duct malignancy exhibiting frequent isocitrate dehydrogenase (IDH1/IDH2) mutations. Through a high-throughput drug screen of a large panel of cancer cell lines, including 17 biliary tr
Autor:
Yuwaraj Kadariya, Andres J. Klein-Szanto, Arti Shukla, Jacqueline Talarchek, Mitchell Cheung, Kathy Q. Cai, Melpo Christofidou-Solomidou, Joseph R. Testa, Craig W. Menges, Ralph A. Pietrofesa, Brooke T. Mossman
Publikováno v:
Cancer Prevention Research. 9:406-414
Exposure to asbestos is causally associated with the development of malignant mesothelioma, a cancer of cells lining the internal body cavities. Malignant mesothelioma is an aggressive cancer resistant to all current therapies. Once inhaled or ingest
Autor:
QT Bui, Keon Wook Kang
Publikováno v:
Cancer Research. 76:P1-05
Epithelial-mesenchymal transition (EMT) is process in which epithelial cells undergo unique morphologic changes characterized by a transition from epithelial cobblestone phenotype to elongated fibroblastic phenotype (mesenchymal phenotype) leading to
Autor:
Dan L. Sackett, Alex Kagansky, Susan E. Bates, Jung-Hyun Kim, Jane B. Trepel, Nicholas C.O. Lee, Hee-Sheung Lee, Yves Pommier, Natalay Kouprina, Vladimir Larionov
Publikováno v:
Cancer Research. 76:902-911
Whole chromosomal instability (CIN), manifested as unequal chromosome distribution during cell division, is a distinguishing feature of most cancer types. CIN is generally considered to drive tumorigenesis, but a threshold level exists whereby furthe
Autor:
Russo, Mariangela, Siravegna, Giulia, Blaszkowsky, Lawrence S., Corti, Giorgio, Crisafulli, Giovanni, Ahronian, Leanne G., Mussolin, Benedetta, Kwak, Eunice L., Buscarino, Michela, Lazzari, Luca, Valtorta, Emanuele, Truini, Mauro, Jessop, Nicholas A., Robinson, Hayley E., Hong, Theodore S., Mino Kenudson, Mari, DI NICOLANTONIO, Federica, Thabet, Ashraf, Sartore Bianchi, Andrea, Siena, Salvatore, Iafrate, John, Bardelli, Alberto, Corcoran, Ryan B., joint co last authorshipjoint corresponding authorship
Publikováno v:
Cancer Discovery. 6:147-153
How genomic heterogeneity associated with acquired resistance to targeted agents affects response to subsequent therapy is unknown. We studied EGFR blockade in colorectal cancer to assess whether tissue and liquid biopsies can be integrated with radi
Autor:
Patricia Haney, Michelle Casey, Keith T. Flaherty, Anne O'Hagan, Ademi Santiago-Walker, Dirk Schadendorf, Vicki L. Goodman, Axel Hauschild, Jeffrey J. Legos, Richard F. Kefford, Robert C. Gagnon, Patrick Hwu, Jolly Mazumdar, Anne-Marie Martin, Georgina V. Long, Jennifer Carver
Publikováno v:
Clinical Cancer Research. 22:567-574
Purpose: Tumor-derived circulating cell–free DNA (cfDNA) is a potential alternative source from which to derive tumor mutation status. cfDNA data from four clinical studies of the BRAF inhibitor (BRAFi) dabrafenib or the MEK inhibitor (MEKi) tramet
Autor:
Randall J. Kimple, Johan Lantto, Zachary S. Morris, David M. Francis, Craig R. Hullett, Eric A. Armstrong, Chunrong Li, Paul M. Harari, Lauryn R. Werner, Adam D. Swick, Michael Kragh, Shyhmin Huang
Publikováno v:
Clinical Cancer Research. 22:633-643
Purpose: Aberrant regulation of the EGF receptor family (EGFR, HER2, HER3, HER4) contributes to tumorigenesis and metastasis in epithelial cancers. Pan-HER represents a novel molecular targeted therapeutic composed of a mixture of six monoclonal anti
Autor:
Michael B. Sporn, Charlotte R. Williams, Martine Cao, Renee Risingsong, Karen T. Liby, Darlene B. Royce
Publikováno v:
Cancer Prevention Research. 9:105-114
LG101506 was originally synthesized to overcome some of the undesirable side effects of rexinoids. We compared the anticarcinogenic action of LG101506 and LG100268 and for the first time showed that both drugs are useful for prevention of lung cancer
Autor:
Katherine A. Hoadley, Ian E. Krop, Maki Tanioka, Sara M. Tolaney, CM Perou, Donald A. Berry, Chau T. Dang, Elaine R. Mardis, EP Winer, Lisa A. Carey, Norah Lynn Henry, Lyndsay Harris, Chun-Yang Fan, Clifford A. Hudis, Terry Hyslop, JA Parker, Brandy Pitcher
Publikováno v:
Cancer Research. 77:S3-05
Background: RNA profiling and mutational analyses in CALGB 40601 (NCT00770809) found significant impact on pathologic complete response (pCR) rates from tumor (intrinsic subtype, p53 mutation) and microenvironmental (immune cell) features. Integrated
Autor:
Harold L. Moses, Tatiana Novitskaya, Samantha C. Schwager, Igor Feoktistov, Timothy S. Blackwell, Georgii Vasiukov, Sergey V. Novitskiy
Publikováno v:
Cancer Research. 80:1714A-1714A
TGF-beta plays a crucial role in tumor microenvironment by regulating cell-cell and cell-stroma interactions. We previously demonstrated that TGF-beta signaling on myeloid cells regulates expression of CD73, a key enzyme for production of adenosine,